Terms: = Brain cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Clinical Outcome
4 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Gandhi P; Khare R; Garg N; Mishra J
J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
[TBL] [Abstract] [Full Text] [Related]
3. Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors.
Colli LM; Saggioro F; Serafini LN; Camargo RC; Machado HR; Moreira AC; Antonini SR; de Castro M
PLoS One; 2013; 8(4):e62424. PubMed ID: 23638078
[TBL] [Abstract] [Full Text] [Related]
4. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma.
Michalowski MB; de Fraipont F; Michelland S; Entz-Werle N; Grill J; Pasquier B; Favrot MC; Plantaz D
Cancer Genet Cytogenet; 2006 Apr; 166(1):74-81. PubMed ID: 16616114
[TBL] [Abstract] [Full Text] [Related]
